Albany Molecular Research (NASDAQ: AMRI) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Albany Molecular Research to similar businesses based on the strength of its profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Insider and Institutional Ownership

72.1% of Albany Molecular Research shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.5% of Albany Molecular Research shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Albany Molecular Research and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Albany Molecular Research $680.81 million $73.33 million -12.08
Albany Molecular Research Competitors $207.79 million -$2.30 million 0.47

Albany Molecular Research has higher revenue and earnings than its peers. Albany Molecular Research is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Albany Molecular Research has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Albany Molecular Research’s peers have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.

Profitability

This table compares Albany Molecular Research and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Albany Molecular Research -5.93% -13.39% -3.42%
Albany Molecular Research Competitors -3,963.62% -118.21% -43.68%

Analyst Ratings

This is a summary of current recommendations for Albany Molecular Research and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Albany Molecular Research 0 4 0 0 2.00
Albany Molecular Research Competitors 480 2263 6187 119 2.66

Albany Molecular Research currently has a consensus price target of $18.00, indicating a potential downside of 17.20%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.56%. Given Albany Molecular Research’s peers stronger consensus rating and higher possible upside, analysts clearly believe Albany Molecular Research has less favorable growth aspects than its peers.

Summary

Albany Molecular Research beats its peers on 7 of the 12 factors compared.

About Albany Molecular Research

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.